News Release

SARS-CoV-2 antibody responses in previously infected individuals after Pfizer/Biontech vaccine

JAMA Network Open

Peer-Reviewed Publication

JAMA Network

What The Study Did: Researchers evaluated the SARS-CoV-2 spike immunoglobin (Ig) G antibody levels after one and two doses of the Pfizer/BioNTech (BNT162b2) SARS-CoV-2 mRNA vaccine in previously infected individuals compared with those without previous
infection.

Authors: James Moy, M.D., of Rush University Medical Center in Chicago, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamanetworkopen.2021.19741)

Editor’s Note: The article includes funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2021.19741?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=080621

About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.